(Q48818384)

15 February 2018

title

Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. (English)

1 reference

15 February 2018

author

Herman Tournaye

5

1 reference

15 February 2018

Paul Devroey

7

object named as

Paul Devroey

1 reference

15 February 2018

André C. Van Steirteghem

6

object named as

Andre Van Steirteghem

1 reference

15 February 2018

author name string

Efstratios Kolibianakis

1

1 reference

15 February 2018

Kostantinos Zikopoulos

2

1 reference

15 February 2018

Carola Albano

3

1 reference

15 February 2018

Michel Camus

4

1 reference

15 February 2018

publication date

1 October 2003

1 reference

15 February 2018

Reproductive BioMedicine Online

published in

1 reference

15 February 2018

volume

7

1 reference

15 February 2018

issue

3

1 reference

15 February 2018

page(s)

313-318

1 reference

15 February 2018

Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Reproductive endocrinologic alterations in female asymptomatic obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Ovulation induction with low-dose follicle-stimulating hormone in women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Gonadotrophin-releasing hormone antagonists: will they replace the agonists?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Gonadotrophin regimens and oocyte quality in women with polycystic ovaries

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Serum FSH levels in women with polycystic ovary syndrome during ovulation induction using down-regulation and urofollitropin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Obesity and the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Serum levels of insulin-like growth factor-1, IGF binding protein-1 and insulin and the response to human menopausal gonadotrophins in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

The place of gonadotrophin-releasing hormone antagonists in reproductive medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Single-dose pharmacokinetics and pharmacodynamics of recombinant human follicle-stimulating hormone (Org 32489*) in gonadotropin-deficient volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Risk factors and prognostic variables in the ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Obesity and reproductive disorders: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

GnRH antagonists: do they open new pathways to safer treatment in assisted reproductive techniques?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

The use of GnRH antagonists in ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Progesterone supplementation during early gestation after in vitro fertilization has no effect on the delivery rate

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Impact of metformin therapy on ovarian stimulation and outcome in 'coasted' patients with polycystic ovary syndrome undergoing in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

Insulin and the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

High fertilization and implantation rates after intracytoplasmic sperm injection.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961870-6

7 January 2021

10.1016/S1472-6483(10)61870-6

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018